The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 2,021 | 2,183 | 3,052 | 3,275 |
| Depreciation expense | 93 | 90 | 90 | 93 |
| Amortization expense | 596 | 597 | 596 | 598 |
| Stock-based compensation expense | 218 | 230 | 230 | 225 |
| Deferred income taxes | 179 | -122 | 659 | -178 |
| Net (gain) loss from equity securities | 142 | 253 | 482 | 142 |
| Acquired in-process research and development expenses | 107 | 539 | 170 | 62 |
| In-process research and development impairments | - | 400 | 0 | 190 |
| Other, net | -183 | -267 | -89 | -33 |
| Accounts receivable, net | -134 | -179 | 333 | 292 |
| Inventories | 52 | 123 | 515 | 175 |
| Prepaid expenses and other | -5 | 36 | 368 | -81 |
| Accounts payable | -67 | -95 | 230 | -162 |
| Income tax assets and liabilities, net | -29 | -134 | -122 | -1,300 |
| Accrued and other liabilities | -702 | -395 | 811 | -166 |
| Net cash provided by operating activities | 2,544 | 3,327 | 4,108 | 827 |
| Purchases of marketable debt securities | 525 | 1,382 | 270 | 2,287 |
| Proceeds from sales of marketable debt securities | 2,520 | 340 | 219 | 295 |
| Proceeds from maturities of marketable debt securities | 36 | 23 | 17 | 15 |
| Acquisitions, including in-process research and development, net of cash acquired | 109 | 609 | 167 | 21 |
| Purchases of equity securities | 19 | 14 | 82 | 21 |
| Purchases of property, plant and equipment | 117 | 205 | 147 | 107 |
| Other investing activities, net | 17 | -11 | -4 | -10 |
| Net cash provided by (used in) investing activities | 1,770 | -1,835 | -427 | -2,116 |
| Proceeds from debt financing, net of issuance costs | - | 0 | - | - |
| Proceeds from issuances of common stock | 166 | 32 | 97 | 27 |
| Repurchases of common stock under repurchase programs | 419 | 230 | 435 | 527 |
| Repayments of debt and other obligations | 2,766 | 8 | 9 | 9 |
| Payments of dividends | 1,040 | 994 | 1,005 | 994 |
| Other financing activities, net | -179 | -63 | -137 | -64 |
| Net cash used in financing activities | -4,239 | -1,263 | -1,489 | -1,567 |
| Effect of exchange rate changes on cash and cash equivalents | -11 | 5 | -5 | 73 |
| Net change in cash and cash equivalents | 65 | 233 | 2,187 | -2,783 |
| Cash and cash equivalents at beginning of period | 7,564 | 7,330 | 5,144 | 7,926 |
| Cash and cash equivalents at end of period | 7,628 | 7,564 | 7,330 | 5,144 |
GILEAD SCIENCES, INC. (GILD)
GILEAD SCIENCES, INC. (GILD)